Skip to main content

Advertisement

SpringerLink
Log in

A three-drug combination to treat BRAF-mutant cancers

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A new study that uses a triple-drug combination to overcome a major mechanism of drug resistance in cancer provides insights into the evolutionary paths taken by tumors in the face of selective pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Sequential inhibition of BRAF pathway components is at a lower fitness threshold than simultaneous inhibition.

References

  1. Pratilas, C.A., Xing, F. & Solit, D.B. Curr. Top. Microbiol. Immunol. 355, 83–98 (2010).

    Google Scholar 

  2. Shi, H. et al. Nat. Commun. 3, 724 (2012).

    Article  Google Scholar 

  3. Larkin, J. et al. N. Engl. J. Med. 371, 1867–1876 (2014).

    Article  Google Scholar 

  4. Long, G.V. et al. N. Engl. J. Med. 371, 1877–1888 (2014).

    Article  Google Scholar 

  5. Xue, Y. et al. Nat. Med. 23, 929–937 (2017).

    Article  CAS  Google Scholar 

  6. Bock, C. & Lengauer, T. Nat. Rev. Cancer 12, 494–501 (2012).

    Article  CAS  Google Scholar 

  7. Brioli, A., Melchor, L., Cavo, M. & Morgan, G.J. Br. J. Haematol. 165, 441–454 (2014).

    Article  Google Scholar 

  8. Das Thakur, M. et al. Nature 494, 251–255 (2013).

    Article  CAS  Google Scholar 

  9. Skoulidis, F. & Papadimitrakopoulou, V.A. Clin. Cancer Res. 23, 618–622 (2017).

    Article  CAS  Google Scholar 

  10. Holderfield, M., Nagel, T.E. & Stuart, D.D. Br. J. Cancer 111, 640–645 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Calico Life Sciences, South San Francisco, California, USA

    Ari J Firestone & Jeff Settleman

Authors
  1. Ari J Firestone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeff Settleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeff Settleman.

Ethics declarations

Competing interests

A.J.F. and J.S. are both employees of Calico Life Sciences.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Firestone, A., Settleman, J. A three-drug combination to treat BRAF-mutant cancers. Nat Med 23, 913–914 (2017). https://doi.org/10.1038/nm.4382

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4382

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation